An open label, single arm, Investigator initiated trial assessing whether treatment with CM-101 reduced inflammatory & fibrotic biomarkers in patients with COVID-19-derived Lung Damage

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Nov 2022 New trial record
09 Nov 2022 According to a Chemomab Therapeutics media release, data from this study were presented at the Union World Conference on Lung Health 2022.
09 Nov 2022 Results published in the Chemomab Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com